Go Pro
LON:GENF

Genflow Biosciences Final Earnings Report

Genflow Biosciences logo
GBX 2.25 +0.05 (+2.27%)
As of 11:55 AM Eastern

Genflow Biosciences EPS Results

Actual EPS
-GBX 0.33
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genflow Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genflow Biosciences Announcement Details

Quarter
Final
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Genflow Biosciences Earnings Headlines

SIRT6 gene therapy shows promise in aged dogs - ICYMI
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
See More Genflow Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genflow Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genflow Biosciences and other key companies, straight to your email.

About Genflow Biosciences

Genflow Biosciences (LON:GENF) is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.

View Genflow Biosciences Profile